Home>>Signaling Pathways>> Others>>Tiopinac (RS 40974)

Tiopinac (RS 40974)

Catalog No.GC31821

Tiopinac (RS 40974) (RS 40974), a dibenzthiepin, is an orally active and highly potent anti-inflammatory and anti-pyretic agent.

Products are for research use only. Not for human use. We do not sell to patients.

Tiopinac (RS 40974) Chemical Structure

Cas No.: 61220-69-7

Size Price Stock Qty
1mg
$184.00
In stock
5mg
$368.00
In stock
10mg
$625.00
In stock
20mg
$1,103.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

Tiopinac is a highly potent anti-inflammatory, analgesic and anti-pyretic agent.

Tiopinac (0.03-110 mg/kg) has 40 times the antiphlogistic potency of phenylbutazone. The dose required to reduce paw swelling by 30% is approximately 0.5 mg/kg. Tiopinac does not elicit overt side effects at the 20 mg/kg/day dose. Tiopinac causes a dose-related reversal of the decreases body weight caused by the adjuvant disease, the weight of those rats receiving 0.135 and 0.4 mg/kg/day being significantly greater than that of the positive controls. Tiopinac (0.3-30 mg/kg) is highly potent in inhibiting the pain evoked in the yeastinflamed hind paw of the rat[1].

[1]. Rooks WH 2nd, et al. The anti-inflammatory and analgesic profile of 6,11-dihydrodibenzo-[b.e.]-thiepin-11-one-3-acetic acid (tiopinac). Agents Actions. 1980 Jun;10(3):266-73.

Reviews

Review for Tiopinac (RS 40974)

Average Rating: 5 ★★★★★ (Based on Reviews and 32 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Tiopinac (RS 40974)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.